89bio Inc (NASDAQ: ETNB)’s stock price has plunge by 4.23relation to previous closing price of 6.62. Nevertheless, the company has seen a 17.15% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-18 that Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better safety profile compared to competitors, potentially capturing significant market share in MASH and SHTG. Financially, 89bio has a solid cash position but may need to raise capital by mid to late 2026, posing dilution risk.
Is It Worth Investing in 89bio Inc (NASDAQ: ETNB) Right Now?
Company’s 36-month beta value is 1.50.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ETNB is 140.34M, and currently, short sellers hold a 10.85% ratio of that floaft. The average trading volume of ETNB on April 25, 2025 was 2.66M shares.
ETNB’s Market Performance
ETNB stock saw a decrease of 17.15% in the past week, with a monthly decline of -13.86% and a quarterly a decrease of -0.29%. The volatility ratio for the week is 7.73%, and the volatility levels for the last 30 days are 12.16% for 89bio Inc (ETNB). The simple moving average for the past 20 days is 8.18% for ETNB’s stock, with a -16.60% simple moving average for the past 200 days.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with Goldman repeating the rating for ETNB by listing it as a “Neutral.” The predicted price for ETNB in the upcoming period, according to Goldman is $11 based on the research report published on March 14, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $25. The rating they have provided for ETNB stocks is “Buy” according to the report published on March 13th, 2025.
ETNB Trading at -14.08% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.72% of loss for the given period.
Volatility was left at 12.16%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares sank -13.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.28% lower at present.
During the last 5 trading sessions, ETNB rose by +17.15%, which changed the moving average for the period of 200-days by -12.66% in comparison to the 20-day moving average, which settled at $6.38. In addition, 89bio Inc saw -11.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from Le-Nguyen Quoc, who sale 15,329 shares at the price of $5.95 back on Apr 15 ’25. After this action, Le-Nguyen Quoc now owns 328,323 shares of 89bio Inc, valued at $91,208 using the latest closing price.
QUOC LE-NGUYEN, the Officer of 89bio Inc, proposed sale 15,329 shares at $5.95 during a trade that took place back on Apr 15 ’25, which means that QUOC LE-NGUYEN is holding shares at $91,171 based on the most recent closing price.
Stock Fundamentals for ETNB
The total capital return value is set at -0.87. Equity return is now at value -78.34, with -68.30 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -9.8. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -72.71.
Currently, EBITDA for the company is -384.66 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.19.
Conclusion
In a nutshell, 89bio Inc (ETNB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
